These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection]. Macías J; Rivero A Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901 [TBL] [Abstract][Full Text] [Related]
5. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Pascale A; Serfaty L J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419 [TBL] [Abstract][Full Text] [Related]
6. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376 [TBL] [Abstract][Full Text] [Related]
7. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin. Selvapatt N; Habibi MS; Brown A J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248 [TBL] [Abstract][Full Text] [Related]
8. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. Wedemeyer H; Forns X; Hézode C; Lee SS; Scalori A; Voulgari A; Le Pogam S; Nájera I; Thommes JA PLoS One; 2016; 11(1):e0145409. PubMed ID: 26752189 [TBL] [Abstract][Full Text] [Related]
9. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Sitole M; Silva M; Spooner L; Comee MK; Malloy M Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368 [TBL] [Abstract][Full Text] [Related]
10. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA]. Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553 [TBL] [Abstract][Full Text] [Related]
11. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? Michielsen P; Ho E; Francque S Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005 [TBL] [Abstract][Full Text] [Related]
12. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Sterling RK; Kuo A; Rustgi VK; Sulkowski MS; Stewart TG; Fenkel JM; El-Genaidi H; Mah'moud MA; Abraham GM; Stewart PW; Akushevich L; Nelson DR; Fried MW; Di Bisceglie AM Aliment Pharmacol Ther; 2015 Apr; 41(7):671-85. PubMed ID: 25627020 [TBL] [Abstract][Full Text] [Related]
13. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
14. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Beste LA; Green PK; Ioannou GN Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739 [TBL] [Abstract][Full Text] [Related]
15. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314 [TBL] [Abstract][Full Text] [Related]
16. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C. Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058 [TBL] [Abstract][Full Text] [Related]
17. Boceprevir: a protease inhibitor for the treatment of hepatitis C. Chang MH; Gordon LA; Fung HB Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763 [TBL] [Abstract][Full Text] [Related]
18. Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'? Foster GR; Serfaty LD Liver Int; 2012 Feb; 32 Suppl 1():61-3. PubMed ID: 22212574 [TBL] [Abstract][Full Text] [Related]
19. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044 [TBL] [Abstract][Full Text] [Related]
20. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]